| Patent application number | Description | Published |
|---|
| 20080221055 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUNTINGTIN GENE - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell. | 09-11-2008 |
| 20080306212 | POLYMER CONJUGATES OF MUTATED NEUBLASTIN - A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin. | 12-11-2008 |
| 20090202562 | ANTI-GFRALPHA3 ANTIBODIES - Antibodies and antibody fragments that bind to the receptor GFRalpha3 and inhibit formation of a Neublastin-GFRalpha3-Ret ternary complex are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit phosphorylation of Ret in a cell and treat disorders and in a subject. | 08-13-2009 |
| 20090221495 | TREATMENTS FOR NEUROLOGICAL DISORDERS - Disclosed are methods of improving impaired proprioception, treating brachial plexus injuries, regenerating large and small nerve fibers, treating dorsal root nerve injuries, and improving sensory neural responses in a subject by administration of a neublastin polypeptide. | 09-03-2009 |
| 20100087508 | Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer. | 04-08-2010 |
| 20100120893 | Compositions and Methods for Inhibiting Expression of Transthyretin - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR. | 05-13-2010 |
| 20100267806 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a lipid formulation, and methods of using the compositions to inhibit the expression of the Human kinesin family member 11 (Eg5) and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer. | 10-21-2010 |
| 20100298405 | Compositions And Methods For Inhibiting Expression Of Huntingtin Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell. | 11-25-2010 |
